Ropinirole XR (Extended Release) In Patients With Restless Legs Syndrome

Ropinirole Tablets In Young Patients With Restless Legs Syndrome

NCT00140712 ·Status: COMPLETED ·Phase: PHASE1

Rotigotine Effect on All-day Functioning and Quality of Life in Subjects With Moderate to Severe Restless Legs Syndrome (RLS)

NCT01569464 ·Status: COMPLETED ·Phase: PHASE3

Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food

NCT00419692 ·Status: COMPLETED ·Phase: PHASE1

Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)

NCT00256854 ·Status: COMPLETED ·Phase: PHASE3

Clinical Evaluation of Ropinirole IR (Immediate Release) Tablets in Patients Who Are Diagnosed With Symptomatic Restless Legs Syndrome (RLS) Associated With Chronic Kidney Disease (CKD) Managed With Haemodialysis (Including Haemofiltration and Haemodiafiltration)

NCT00996944 ·Status: TERMINATED ·Phase: PHASE2

SWITCH:Restless Legs Patients Switched to Ropinirole From Pramipexole

NCT00344994 ·Status: COMPLETED ·Phase: PHASE4

Safety and Efficacy Study of IPX159 in Restless Legs Syndrome (RLS)

NCT01521663 ·Status: COMPLETED ·Phase: PHASE2

Effect of Ropinirole on Spinal Cord Reflexes and Restless Legs Syndrome

NCT00051961 ·Status: COMPLETED

Effects of Neupro on Cardiovascular Observations in Patients With Restless Legs Syndrome

NCT01455012 ·Status: COMPLETED ·Phase: PHASE4

Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome

NCT01823770 ·Status: COMPLETED ·Phase: PHASE4

Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome

NCT00136045 ·Status: COMPLETED ·Phase: PHASE3

Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome

NCT02025608 ·Status: COMPLETED ·Phase: PHASE4

A Study in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.)

NCT00152958 ·Status: COMPLETED ·Phase: PHASE3

Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)

NCT00367822 ·Status: COMPLETED ·Phase: PHASE3

Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome

NCT00135993 ·Status: COMPLETED ·Phase: PHASE3

Treatment of Restless Legs Syndrome With the Hypocretin Antagonist Suvorexant

NCT03755310 ·Status: UNKNOWN ·Phase: PHASE2

A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS

NCT00627003 ·Status: COMPLETED ·Phase: PHASE3

Clinical Trial Assessing the Efficacy and Safety of BP1.4979 in Restless Legs Syndrome

NCT03345953 ·Status: TERMINATED ·Phase: PHASE2

Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist

NCT03218969 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Switching From Oral Dopamine Agonists to Rotigotine

NCT01976871 ·Status: COMPLETED ·Phase: PHASE4

Phase 3 Open-label Extension Trial With Rotigotine in Idiopathic Restless Legs Syndrome Subjects

NCT00498108 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Pramipexole Compared to Placebo in the Treatment of Restless Legs Syndrome (RLS)

NCT00133198 ·Status: COMPLETED ·Phase: PHASE3

XP13512 (GSK1838262) Versus Placebo in Patients With Restless Legs Syndrome.

NCT00298623 ·Status: COMPLETED ·Phase: PHASE3

Long-Term Follow-Up Study for Safety, Efficacy and Tolerability of Rotigotine in Adolescents With Restless Legs Syndrome

NCT01498120 ·Status: COMPLETED ·Phase: PHASE2

Long-term Efficacy, Safety and Tolerability of Pramipexole in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome (RLS)

NCT00472199 ·Status: COMPLETED ·Phase: PHASE4